Back to companies

Xencor Inc: Overview

Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Xencor Inc (Xencor) is a biopharmaceutical company that discover and develops engineered monoclonal antibodies and cytokines for the treatment of cancer.The company’s pipeline program includes XmAb717 for mCRPC, an oncology indications; Tidutamab, a bispecific antibody for the treatment of merkel cell carcinoma, small cell lung cancer and neuroendocrine tumors; Obexelimab, a monoclonal antibody against systemic lupus erythematosus; XmAb104 for treatment of patients with advanced solid tumors ;Plamotamab, a tumor-targeted antibody targeting B-cell tumors; and Vibecotamab to treat acute myeloblastic leukemia. It is also investigating various drug development programs for autoimmune, renal cell carcinoma and in therapeutic area of oncology. Xencor utilizes its proprietary XmAb technology platform to develop next generation antibody product candidates. The company works in collaboration with Alexion Pharmaceuticals Inc, Morphosys AG, Genentech Inc, Amgen Inc and Novartis to conduct research and development activities. Xencor is headquartered in Monrovia, California, the US.

Headquarters United States of America

Address 111 W Lemon Ave, Monrovia, California, 91016-2809


Telephone 1 626 3055900

No of Employees 254

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange XNCR (NASD)

Revenue (2021) $275.1M 124.2% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX 219.2% (2021 vs 2020)

Market Cap* $1.4B

Net Profit Margin (2021) XXX 153.2% (2021 vs 2020)

* As of and is in US$

Products and Services

Products Services Brands
XmAb717 - mCRPC and Oncology Indications Clinical Trials XmAb
Tidutamab - Merkel Cell Carcinoma, Small Cell Lung Cancer and Neuroendocrine Tumors Obexelimab - Systemic Lupus Erythematosus
Plamotamab - B-Cell Tumors
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2021 Contracts/Agreements In October, the company and Janssen Biotech entered into an agreement for the development and commercialization of plamotamab and XmAb CD28 bispecific antibody combinations to treat patients with B-cell malignancies.
2021 Corporate Changes/Expansions In July, the company announced to relocate to the campus from its current headquarters and lab space in Monrovia.
2021 Contracts/Agreements In May, the company and Bristol-Myers Squibb Company entered into a technology license agreement to use Xtend XmAb technology in SARS-CoV-2 neutralizing monoclonal antibody to treat COVID-19.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Xencor Inc Pfizer Inc F. Hoffmann-La Roche Ltd AbbVie Inc Novartis AG
Headquarters United States of America United States of America Switzerland United States of America Switzerland
City Monrovia New York Basel North Chicago Basel
State/Province California New York - Illinois -
No. of Employees 254 79,000 100,920 50,000 110,000
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Net Income Growth

Image for loader
Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Bassil I Dahiyat, Ph.D. Chief Executive Officer; Director; President Executive Board 2005 50
John J Kuch Chief Financial Officer; Senior Vice President Senior Management 2010 61
Allen Yang, Ph.D., M.D. Chief Medical Officer; Senior Vice President Senior Management 2019 53
John R Desjarlais, Ph.D. Senior Vice President - Research; Chief Scientific Officer Senior Management 2014 56
Celia Eckert General Counsel; Secretary; Vice President Senior Management 2019 49
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer